Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Launched by UNIVERSITY OF VIRGINIA · Oct 17, 2019

Keywords

ClinConnect Summary

The proposed study will determine the effect of GLP-1 infusion on microvascular perfusion and microvascular insulin responses in both skeletal and cardiac muscle microvasculature in humans with T1DM. The investigators will study 20 participants with T1DM using a state-of-the-art technology, contrast enhanced ultrasound (CEU), to assess whether GLP-1 augments skeletal and cardiac microvascular blood flow (MBF) as a representation of microvascular perfusion, flow-mediated dilation (FMD) as a measurement of endothelial function, and augmentation index (AI) and pulse wave velocity (PWV) as surr...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. History of type 1 diabetes, duration \> 1 year
• • 2. Age 18-40 years
• • 3. HbA1c \< 8.5%
• • 4. BMI \>/=18, \<30 kg/m2
• • 5. Using insulin for diabetes treatment only
• • 6. On stable regimen of non-diabetic medications for the last 6 months, excluding oral contraceptives (OCP)
• • 7. All screening labs within normal limits or not clinical significant
• Exclusion Criteria:
• • 1) Pregnancy or currently breastfeeding 2) Smoking history within 6 months 3) History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) 4) Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers) 5) OCP use within 3 months or 1 month if menses has subsequently occurred 6) Known hypersensitivity to perflutren (contained in Definity© contrast) 7) Screening O2 saturation\<90% 8) Anemia (hemoglobin \<12 g/dL in women, hemoglobin \<13 g/dL in men) 9) Diabetic ketoacidosis (DKA) on presentation to screening visits or study admission days
• • -